Biotech Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Sangamo Biosciences, Inc. (NASDAQ:SGMO), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Gilead Sciences Inc. (NASDAQ:GILD) EVP Norbert W. Bischofberger sold 90,000 shares of Gilead Sciences stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $80.90, for a total transaction of $7,281,000.00. Following the transaction, the executive vice president now directly owns 119,302 shares in the company, valued at approximately $9,651,532. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is -1.67%. On last trading day company shares ended up $79.47. Analysts mean target price for the company is $100.57. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 2.46%.
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Director Gary E. Frashier sold 55,000 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $8.00, for a total value of $440,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares advanced 1.45% in last trading session and ended the day on $7.69. ACHN return on assets is -37.40%.Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) quarterly performance is 122.25%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Elaine Ullian sold 2,500 shares of the stock on the open market in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $75.00, for a total transaction of $187,500.00. Following the completion of the sale, the director now directly owns 5,265 shares of the company’s stock, valued at approximately $394,875. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares moved down -1.23% in last trading session and was closed at $65.08, while trading in range of $64.19 – $66.30. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) year to date (YTD) performance is -12.41%.
Sangamo Biosciences Inc. (NASDAQ:SGMO) CEO Edward O. Lanphier II sold 25,000 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $16.41, for a total transaction of $410,250.00. Following the completion of the sale, the chief executive officer now directly owns 295,000 shares in the company, valued at approximately $4,840,950. Sangamo Biosciences, Inc. (NASDAQ:SGMO) ended the last trading day at $16.33. Company weekly volatility is calculated as 5.38% and price to cash ratio as 5.20.Sangamo Biosciences, Inc. (NASDAQ:SGMO) showed a positive weekly performance of 0.80%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CEO Uli Hacksell unloaded 20,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $23.10, for a total value of $462,000.00. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) weekly performance is 3.82%. On last trading day company shares ended up $23.67. Analysts mean target price for the company is $31.86. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) distance from 50-day simple moving average (SMA50) is 16.62%.